On the recordMarch 9, 2015
Then I would be remiss if I didn't mention at the same time, biosimilar pathways and the fact that we have yet to have that final guidance.
Source
congress.govEditor's note · Context
Burr emphasizes the need for final guidance on biosimilar pathways.
Share & report
More from Richard Burr
Jan 10, 2022
I am not questioning the science. I am glad you refrained from testing mandates, but I am questioning your communication strategies.
Mar 21, 2022
non-subsidy providers would need to increase prices charged to parents. Those serving families who could not afford to pay higher cost might be forced to close.
Jan 10, 2022
I get what you are doing. My question is this, what does this say to the innovative company that is out there that doesn't have the manufacturing capacity, and without us marrying them to a large manufacturing capacity, it is basically…
Jan 10, 2022
So is that ASPR or is that DOD? Because of all the notifications of contracts signed, I have seen them from DOD.
Other voices in this conversation
